FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Des

09.02.2023 - NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of ... Seite 1

Related Keywords

United States , , Mesoblast Limited Nasdaq , Drug Administration , Office Of Tissues , States Food , Advanced Therapies , Regenerative Medicine Advanced Therapy , Fast Track , Biologics License Application ,